MedPath

Identification of neutralizing antibodies against severe or chronic infections of human being

Recruiting
Conditions
Patients suffering from chronic infections or passing trough server infections within the last 10 years
Registration Number
DRKS00010169
Lead Sponsor
niversitätsklinikum Köln
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Recruiting
Sex
All
Target Recruitment
1000
Inclusion Criteria

Patients suffering from chronic infections or passing trough severe infections within the last 10 years or healthy people as volunteers, and Karnofsky > 80

Exclusion Criteria

-Leukopenia < 2.000 Leukocytes/µl
-Hb < 10 g/dl
-Platelets < 50.000 Plateelts/µl
-Known acquired or hereditary coagulation disorder, including anticoaguant treatment
-CHF NYHA II-IV
-COPD GOLD Stadium III-IV
-History of myocardial infarcation or current symptomatic coronary artery disease
-Symptomatic cardiac or pulmonary disease
-Body weight below 45 kg (for an apheresis or blood draw of > 250 mL, a body weight of 50 kg is required)
-< 8 (men) or 12 (women) weeks since last blood donation or blood draw volume of > 100 mL
-Within 1 week after small surgery (biopsy, tooth extraction), or within 1 month after larger surgery (e.g., thoracotomoy, open abdominal surgery) or surgery with high risk of postoperative bleeding (e.g., tonsillectomy)
-Acute or unknown health deterioration
-Participation in another interventional study

If a leukapheresis is planned, the following additional exclusion criteria apply:

-History of significant complication from leukapheresis or citrate-based anticoagulation
-INR > 1.5 or aPTT > 60 s
-Premenopausal women that cannot rule out pregnancy at the time of apheresis

Study & Design

Study Type
observational
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Identification of neutralizing antibodies. Following methods are used:<br>1. isolation of B cells via flow cytometry ; 2. gene sequencing of antigen-coding central regions; 3. cloning and expression of identified genes; 4. functional analysis of rebuild antibodies using binding studies (ELISA, Biacore) and neutralization testings
Secondary Outcome Measures
NameTimeMethod
© Copyright 2025. All Rights Reserved by MedPath